Repligen
RGEN
#2090
Rank
S$12.67 B
Marketcap
S$224.66
Share price
-3.16%
Change (1 day)
43.11%
Change (1 year)
Categories

Repligen (RGEN) - Total debt

Total debt on the balance sheet as of March 2026 : S$0.87 Billion

According to Repligen 's latest financial reports the company's total debt is S$0.87 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Repligen - Total debt on balance sheet (from 2004 to 2026)

Total debt by year

Year Total debt Change
2025-12-31S$0.88 B-5.04%
2024-12-31S$0.93 B-0.77%
2023-12-31S$0.94 B65.79%
2022-12-31S$0.56 B14.58%
2021-12-31S$0.49 B35.82%
2020-12-31S$0.36 B2.64%
2019-12-31S$0.35 B151.1%
2018-12-31S$0.14 B6.5%
2017-12-31S$0.13 B-3.73%
2016-12-31S$0.13 B
2005-03-31S$0.19 M38.97%
2004-03-31S$0.14 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Pfizer
PFE
S$81.22 B 9,168.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
S$55.00 B 6,176.87%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
S$24.41 B 2,685.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
S$59.17 B 6,651.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
S$24.63 M-97.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
S$0.37 B-57.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
S$0.51 B-40.93%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
S$0.37 B-57.78%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
S$1.83 B 109.36%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
S$3.89 B 344.47%๐Ÿ‡บ๐Ÿ‡ธ USA